{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:10:20Z","timestamp":1785510620007,"version":"3.56.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007543","name":"French Health Products Safety Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106177","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:35:18Z","timestamp":1783751718000},"page":"106177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative analysis of non-clinical and clinical safety assessment of COVID 19 vaccines"],"prefix":"10.1016","volume":"171","author":[{"given":"Camille","family":"Gonin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Crommelynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Kayrouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chollet-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Louin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-0365","authenticated-orcid":false,"given":"Marc","family":"Pallardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.yrtph.2026.106177_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272691","article-title":"Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines\u2013early experience with vaccine rollout in a multi-site healthcare system","volume":"17","author":"Al-Obaydi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2026.106177_bib2","article-title":"Dossier th\u00e9matique\u2014Surveillance de la campagne vaccinale cont","year":"2022","journal-title":"ANSM"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106177_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2515\/therapie\/2011073","article-title":"R\u00e9actualisation de la m\u00e9thode fran\u00e7aise d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments","volume":"66","author":"Arimone","year":"2011","journal-title":"Therapie"},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2026.106177_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-5728(02)00468-X","article-title":"IL-1beta-dependent neurological effects of the whole cell pertussis vaccine: a role for IL-1-associated signalling components in vaccine reactogenicity","volume":"136","author":"Armstrong","year":"2003","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106177_bib6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1503\/cmaj\/051291","article-title":"Troponin: the biomarker of choice for the detection of cardiac injury","volume":"173","author":"Babuin","year":"2005","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"49","key":"10.1016\/j.yrtph.2026.106177_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"issue":"21","key":"10.1016\/j.yrtph.2026.106177_bib8","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2003608","article-title":"A novel circulating noncoding small RNA for the detection of acute myocarditis","volume":"384","author":"Blanco-Dom\u00ednguez","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2026.106177_bib9","article-title":"How correspondence analysis works (A simple explanation)","author":"Bock","year":"2017","journal-title":"Displayr"},{"key":"10.1016\/j.yrtph.2026.106177_bib10","article-title":"How to interpret correspondence analysis plots (it probably isn't the way you think)","author":"Bock","year":"2017","journal-title":"Displayr"},{"issue":"24","key":"10.1016\/j.yrtph.2026.106177_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126252","article-title":"Risk of heavy menstrual bleeding following COVID-19 vaccination: a nationwide case-control study","volume":"42","author":"Botton","year":"2024","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106177_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.yrtph.2026.106177_bib13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.vaccine.2019.02.015","article-title":"Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans","volume":"37","author":"Burny","year":"2019","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.yrtph.2026.106177_bib14","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.3390\/jcm12237214","article-title":"Biomarkers in acute myocarditis and chronic inflammatory cardiomyopathy: an updated review of the literature","volume":"12","author":"Crisci","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yrtph.2026.106177_bib15","article-title":"The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: a 2-year experience report","author":"Crommelynck","year":"2024","journal-title":"Therapies"},{"issue":"19","key":"10.1016\/j.yrtph.2026.106177_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196126","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis (VITT)\u2014Insights from clinical cases, in vitro studies and murine models","volume":"12","author":"Dabbiru","year":"2023","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106177_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2026.106177_bib18","series-title":"Summary Of Product Characteristics - Comirnaty","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106177_bib19","series-title":"COVID-19 Guidance: Evaluation and Marketing Authorisation","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106177_bib21","series-title":"Summary Of Product Characteristics - Nuvaxovid","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106177_bib22","series-title":"Summary Of Product Characteristics - Spikevax","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106177_bib23","series-title":"Summary of product characteristics- vaxzevria","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106177_bib26","series-title":"Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24\u201427 October 2022","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106177_bib24","series-title":"Comirnaty and Spikevax: Possible Link to Very Rare Cases of Myocarditis and Pericarditis","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106177_bib25","series-title":"Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 October 2021","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106177_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.yrtph.2026.106177_bib28","series-title":"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials","year":"2007"},{"key":"10.1016\/j.yrtph.2026.106177_bib29","volume":"24","year":"2023","journal-title":"Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry"},{"key":"10.1016\/j.yrtph.2026.106177_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-0716-1892-9_8","article-title":"Developments in vaccine adjuvants","volume":"2412","author":"Firdaus","year":"2022","journal-title":"Methods Mol. Biol.(Clifton, N.J.)"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106177_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.amepre.2022.09.002","article-title":"A systematic review and meta-analysis of the association between SARS-CoV-2 vaccination and myocarditis or pericarditis","volume":"64","author":"Gao","year":"2023","journal-title":"Am. J. Prev. Med."},{"issue":"8","key":"10.1016\/j.yrtph.2026.106177_bib32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40264-024-01426-4","article-title":"COVID-19 vaccines and heavy menstrual bleeding: the impact of media attention on reporting to EudraVigilance","volume":"47","author":"Gordillo-Mara\u00f1\u00f3n","year":"2024","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106177_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40264-020-01034-y","article-title":"French pharmacovigilance public system and COVID-19 pandemic","volume":"44","author":"Grandvuillemin","year":"2021","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106177_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2022.02.004","article-title":"Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"59","author":"Greinacher","year":"2022","journal-title":"Semin. Hematol."},{"issue":"22","key":"10.1016\/j.yrtph.2026.106177_bib35","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.yrtph.2026.106177_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tibs.2021.03.002","article-title":"COVID-19 vaccines based on adenovirus vectors","volume":"46","author":"Hasanpourghadi","year":"2021","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.yrtph.2026.106177_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.therap.2023.03.002","article-title":"Monitoring the safety of drugs and COVID-19 vaccines by the French pharmacovigilance centers during the pandemic: a win-win bet with health authorities","volume":"78","author":"Jonville-Bera","year":"2023","journal-title":"Therapie"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib41","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.yrtph.2026.106177_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663280","article-title":"Review: Vaccine myth-buster \u2013 cleaning up with prejudices and dangerous misinformation","volume":"12","author":"L\u00f6ffler","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/22221751.2022.2026742","article-title":"WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20-22 April 2021","volume":"11","author":"Liu","year":"2022","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.yrtph.2026.106177_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2022.111093","article-title":"Impact of media coverage on side effect reports from the COVID-19 vaccine","volume":"164","author":"MacKrill","year":"2023","journal-title":"J. Psychosom. Res."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106177_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeab014","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions","volume":"1","author":"Marchandot","year":"2021","journal-title":"European Heart Journal Open"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106177_bib46","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.yrtph.2026.106177_bib47","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.4049\/jimmunol.162.7.4311","article-title":"The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model","volume":"162","author":"McKenzie","year":"1999","journal-title":"Journal of Immunology (Baltimore, Md.: 1950"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib49","first-page":"44","article-title":"Covid- 19 vaccine-induced myocarditis","volume":"13","author":"Munjal","year":"2023","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106177_bib50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tox.2007.12.006","article-title":"Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity","volume":"245","author":"O'Brien","year":"2008","journal-title":"Toxicology"},{"issue":"8","key":"10.1016\/j.yrtph.2026.106177_bib51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10654-020-00675-8","article-title":"Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy","volume":"35","author":"Palamenghi","year":"2020","journal-title":"Eur. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106177_bib52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3892\/etm.2022.11648","article-title":"Evaluation of biomarkers for doxorubicin-induced cardiac injury in rats","volume":"24","author":"Pan","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.yrtph.2026.106177_bib53","article-title":"Potential anionic substances binding to platelet factor 4 in vaccine-induced thrombotic thrombocytopenia of ChAdOx1-S vaccine for SARS-CoV-2","volume":"12","author":"Pang","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050467","article-title":"Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials","volume":"9","author":"Pormohammad","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.yrtph.2026.106177_bib55","first-page":"1","article-title":"Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations","author":"Power","year":"2022","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib56","doi-asserted-by":"crossref","first-page":"904","DOI":"10.4049\/jimmunol.2300185","article-title":"A predictive model of vaccine reactogenicity using data from an in vitro human innate immunity assay system","volume":"212","author":"Pullen","year":"2024","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106177_bib57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1177\/0192623310382438","article-title":"Troponin as a biomarker of cardiac toxicity: past, present, and future","volume":"38","author":"Reagan","year":"2010","journal-title":"Toxicol. Pathol."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"MRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106177_bib59","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/vaccines12070802","article-title":"Reactogenicity differences between adjuvanted, protein-based and messenger ribonucleic acid (mRNA)-Based COVID-19 vaccines","volume":"12","author":"Rousculp","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.yrtph.2026.106177_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1155727","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?","volume":"10","author":"Roytenberg","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.yrtph.2026.106177_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.yrtph.2026.106177_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106177_bib63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0192623319875085","article-title":"Scientific and regulatory policy committee points to consider\u2217: approaches to the conduct and interpretation of vaccine safety studies for clinical and anatomic pathologists","volume":"48","author":"Sellers","year":"2020","journal-title":"Toxicol. Pathol."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106177_bib64","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.vaccine.2021.11.074","article-title":"Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"40","author":"Sexson Tejtel","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib65","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2189885","article-title":"The Matrix-MTM adjuvant: a critical component of vaccines for the 21st century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106177_bib66","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11897-022-00569-8","article-title":"Biomarkers for myocarditis and inflammatory cardiomyopathy","volume":"19","author":"Suresh","year":"2022","journal-title":"Curr. Heart Fail. Rep."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106177_bib67","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","article-title":"Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis","volume":"21","author":"Sutton","year":"2022","journal-title":"Expert Rev. Vaccine"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib68","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/14760584.2023.2208216","article-title":"Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses","volume":"22","author":"Tiozzo","year":"2023","journal-title":"Expert Rev. Vaccine"},{"issue":"11","key":"10.1016\/j.yrtph.2026.106177_bib69","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0300-483X(02)00055-0","article-title":"Non-clinical vaccine safety assessment","volume":"174","author":"Verdier","year":"2002","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib71","first-page":"1","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56994-8","article-title":"Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium","volume":"9","author":"Weiner","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib73","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12916-023-03064-6","article-title":"Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study","volume":"21","author":"Werner","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.yrtph.2026.106177_bib75","volume":"2","year":"2014","journal-title":"WHO-Guidelines on the non-clinical evaluation of vaccine adjuvants and adjuvanted vaccines, Annex"},{"key":"10.1016\/j.yrtph.2026.106177_bib77","series-title":"WHO COVID-19 Dashboard","year":"2024"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106177_bib78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106177_bib79","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.4049\/jimmunol.1900196","article-title":"Regulatory T cells control PF4\/heparin antibody production in mice","volume":"203","author":"Zheng","year":"2019","journal-title":"J. Immunol.(Baltimore, Md. : 1950)"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:33:58Z","timestamp":1785508438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":73,"alternative-id":["S0273230026001509"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106177","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of non-clinical and clinical safety assessment of COVID 19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106177"}}